ISSN: 2235-1795

Journal Home

Journal Guideline

Liver Cancer Q1 Unclaimed

S. Karger AG Switzerland

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Liver Cancer is a journal indexed in SJR in Oncology and Hepatology with an H index of 48. It has an SJR impact factor of 2,955 and it has a best quartile of Q1. It has an SJR impact factor of 2,955.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Hepatology (Q1) Oncology (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

2,955

SJR Impact factor

48

H Index

46

Total Docs (Last Year)

172

Total Docs (3 years)

1841

Total Refs

1604

Total Cites (3 years)

138

Citable Docs (3 years)

9.8

Cites/Doc (2 years)

40.02

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

CA - A Cancer Journal for Clinicians Q1
Molecular Cancer Q1
JAMA oncology Q1
Cancer Discovery Q1
Journal of Hematology and Oncology Q1

Compare this journals

Aims and Scope

Best articles by citations

Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Methodological Limitations to the Analysis by Cicalese et al.

Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status

Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI

Management of Hepatocellular Carcinoma in Japan: Current Trends

Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?

Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment

Association of Serum Ferritin with Diabetes and Alcohol in Patients with Non-Viral Liver Disease-Related Hepatocellular Carcinoma

Hepatic Artery Embolization Induces the Local Overexpression of Transforming Growth Factor beta1 in a Rat Hepatoma Model

Short-Term Results of Laparoscopic Radiofrequency Ablation Using a Multipolar System for Localized Hepatocellular Carcinoma

Clinical Factors Predicting Better Survival Outcome for Pulmonary Metastasectomy of Hepatocellular Carcinoma

Insufficient Ablative Margin Determined by Early Computed Tomography May Predict the Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation

SHOW MORE ARTICLES

Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial

Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review

Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment

Current Status of Hepatic Arterial Infusion Chemotherapy

Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients

Response to the Comments on Cicalese et al.: "An Ecological Study of the Association between Air Pollution and Hepatocellular Carcinoma Incidence in Texas"

Surgery of Colorectal Liver Metastases: Pushing the Limits

Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions

Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected

Liver Transplantation for Hepatocellular Carcinoma

Response to the Letter to the Editor Concerning the Publication "Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma"

Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma